Zhongguancun Bank Unveils Prospectus Highlighting Dedicated Financial Solutions for the Medical and Health Industry at CSGCT Conference

Beijing Zhongguancun Bank is China’s first private bank dedicated to serving technological innovation. Over the past eight years since its establishment, Beijing Zhongguancun Bank has remained deeply rooted in Zhongguancun, a fertile ground for innovation and entrepreneurship, committed to fulfilling its mission as a purpose-driven bank. This mission is “to help entrepreneurs realize their dreams,” positioning itself as “the bank for innovators and entrepreneurs.” Differing from the “large and comprehensive” service model of traditional commercial banks, Beijing Zhongguancun Bank has adopted a technology finance development strategy, with a sharper focus on serving sci-tech innovation and prioritizing the “Three Innovations” (Makers, Venture Capital, and Innovative Enterprises), exploring the deep integration of technology and finance, and forming a virtuous cycle of high-quality operational development.

Since its establishment, Beijing Zhongguancun Bank has prioritized the healthcare sector as a key focus in its tech-finance strategy. Through years of dedicated efforts, the bank has built a specialized service system covering the entire industry chain, addressing financing challenges while pioneering a distinctive path for tech-finance to empower industrial upgrading.

As of mid-2025, Beijing Zhongguancun Bank had served over 300 healthcare companies in the Beijing area, with more than 200 of them receiving credit support. The cumulative credit amount reached RMB 5 billion, covering four major sub-sectors: drug research and development and manufacturing, high-end medical devices, CXO services, and medical commerce. The bank places particular emphasis on disruptive frontier biotechnologies, including gene therapy and cell therapy, and has made proactive strategic investments in these areas. Notably, 30% of the bank’s corporate clients were “first-time borrowers” obtaining bank financing for the first time, and 70% were not yet profitable. Beijing Zhongguancun Bank’s professional expertise has been highly recognized by its clients and partners, establishing strong brand influence and a positive reputation within the healthcare industry.

By recruiting professionals in medicine, pharmacy, and bioengineering, as well as engaging external expert consultants, Zhongguancun Bank has built specialized marketing and credit review and approval teams, and established more targeted due diligence procedures, criteria for review and approval, and post-loan management requirements.

The bank’s marketing and business departments continuously conduct in-depth research into various sub-sectors of the healthcare industry, while the credit approval department regularly publishes the Overview and Credit Risk Control Manual for the Pharmaceutical R&D and Manufacturing Industry, leveraging comprehensive and robust industry insights to support business expansion and customer service.

In light of the common characteristics of innovative pharmaceutical companies, such as long R&D cycles and high demands for capital stability, Bank of Zhongguancun (Beijing) has introduced long-term technology R&D loans to meet enterprises’ funding needs for scientific and technological research and development. The bank’s flagship product, the “Warrant Loan,” adopts a “debt financing + warrants” structure, using the potential returns from warrants to offset credit risks. This approach not only reduces the current financing costs for enterprises but also allows the bank to share in the future growth dividends of these companies. In line with the industry trend where leading pharmaceutical companies enhance their technological capabilities and expand market share through external growth, Bank of Zhongguancun (Beijing) has developed flexible M&A loan products with high loan-to-value ratios to help enterprises scale up and strengthen their competitive position.

Beijing Zhongguancun Bank Embraces Cutting-Edge AI Technology to Continuously Optimize and Enhance Operational Capabilities. Leveraging its accumulation of historical industry data, Beijing Zhongguancun Bank has integrated artificial intelligence into its credit assessment process, establishing a specialized evaluation model tailored for healthcare companies. This approach not only improves the efficiency of project assessments but also reduces biases associated with subjective judgment. Focusing on multiple factors such as “sector-specific value, financing health, pipeline competitive landscape, technological potential and valuation, and commercialization prospects,” the model moves away from excessive reliance on traditional financial metrics. Instead, it reconstructs the risk assessment framework based on industrial logic, achieving favorable practical outcomes.

The growth of healthcare enterprises requires synergistic efforts between finance and industry. By building a “Finance + Ecosystem” service model, Beijing Zhongguancun Bank has transformed from a mere capital provider into a “long-term companion” for corporate growth. Partnering with investment institutions, financial entities, incubators and accelerators, hospitals and medical schools, and pharmaceutical industrial parks that specialize in the healthcare sector, Beijing Zhongguancun Bank jointly empowers enterprise development, providing clients with comprehensive support encompassing funding, industrial resources, and talent assurance.

The cutting-edge breakthroughs and commercialization of cell and gene therapy (CGT) technologies are inseparable from the support of the financial services system. Bank of Zhongguancun Beijing will continue to leverage its professional strengths in sci-tech finance, drawing on its extensive experience in the healthcare industry. By adopting a forward-looking approach and pursuing continuous innovation, the bank is committed to providing more precise financial support to CGT enterprises through the ongoing iteration of its financial products and service models, serving as a long-term companion to entrepreneurs in the healthcare sector.

The 2025 China Society for Gene and Cell Therapy (CSGCT) Conference will be grandly held at the Beijing Zhongguancun National Independent Innovation Demonstration Zone Exhibition and Trading Center on September 12–13, 2025., Beijing Zhongguancun Bank cordially invites you to attend the conference and join us in this grand event!

To drive technological breakthroughs, industrial integration, policy alignment, and international cooperation in China’s cell and gene therapy (CGT) sector, and to propel the Chinese CGT industry to the forefront of global competition, the China Society for Gene and Cell Therapy (CSGCT) Conference was established.

Leveraging its close ties with the American Society of Gene & Cell Therapy (ASGCT), the 2025 CSGCT Annual Meeting will bring together leading scientists, clinical experts, multinational pharmaceutical companies, and overseas investment institutions from around the world. The event will showcase the most cutting-edge scientific advances, technologies, applications, market access information, and high-quality collaborative projects in the global cell and gene therapy sector, while facilitating matchmaking between overseas investors and investment opportunities. It aims to build a platform for in-depth exchange and cooperation between China’s cell and gene therapy industry and the global value chain.

The conference closely addressed the industry's hotspots, pain points, and bottlenecks, featuring1 Main Forum + 15 High-End Sub-Forums, covering the latest advances in global gene therapy, immune cell therapy, in vivo CAR-T, adult stem cells and exosomes, iPSC-derived cell therapies, small nucleic acid drugs, gene editing, oncolytic viruses, tumor vaccines, and other fields, as well as clinical applications and breakthroughs, CMC and testing, AI-driven drug R&D, registration and regulation, investment and financing, and BD matchmaking.Comprehensive Coverage of the Entire Industry Chain.

2025 2nd China Society for Gene and Cell Therapy (CSGCT) Conference

September 12-13, 2025

Zhongguancun National Independent Innovation Demonstration Zone Exhibition and Trading Center [Conference Center]

For more details, please scan the QR code to visit the official conference website.